Literature DB >> 10882721

The generation and characterization of antagonist RNA aptamers to human oncostatin M.

A Rhodes1, A Deakin, J Spaull, B Coomber, A Aitken, P Life, S Rees.   

Abstract

Oncostatin M (OSM) is a multifunctional member of the interleukin-6 cytokine family. OSM has been implicated as a powerful proinflammatory mediator and may represent a potentially important, novel therapeutic opportunity for treatment of established rheumatoid arthritis. To further investigate the role of OSM in inflammatory disorders, we have isolated a series of RNA aptamers that bind specifically to human OSM. The highest affinity aptamer, designated ADR58, has been characterized in a series of in vitro and cell based assays. ADR58 has an affinity of 7 nm for human OSM, and it can antagonize OSM binding to the gp130 receptor and specifically antagonize OSM mediated signaling. The aptamer has been truncated in length to 33 bases, all pyrimidine positions are substituted with 2' fluorine, and 14 of 18 purine positions have been substituted with 2' O-methyl to increase stability toward nucleases. This truncated, modified form of ADR58 retains complete affinity and functional activity for OSM. This aptamer may be used as a tool to further investigate the role of OSM in inflammatory disorders and may also have role as a therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882721     DOI: 10.1074/jbc.M002981200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Recent developments in protein and cell-targeted aptamer selection and applications.

Authors:  Jun Liu; Mingxu You; Ying Pu; Huixia Liu; Mao Ye; Weihong Tan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 2.  Aptamers in immunotherapy.

Authors:  Claudia M Dollins; Smita Nair; Bruce A Sullenger
Journal:  Hum Gene Ther       Date:  2008-05       Impact factor: 5.695

3.  Aptamers that preferentially bind type IVB pili and inhibit human monocytic-cell invasion by Salmonella enterica serovar typhi.

Authors:  Qin Pan; Xiao-Lian Zhang; Hong-Yan Wu; Pan-Wen He; Fubin Wang; Ming-Sheng Zhang; Jian-Ming Hu; Bing Xia; Jianguo Wu
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  TLR4-Binding DNA Aptamers Show a Protective Effect against Acute Stroke in Animal Models.

Authors:  Gerónimo Fernández; Ana Moraga; María I Cuartero; Alicia García-Culebras; Carolina Peña-Martínez; Jesús M Pradillo; Macarena Hernández-Jiménez; Silvia Sacristán; M Irene Ayuso; Rafael Gonzalo-Gobernado; David Fernández-López; M Elena Martín; María A Moro; Victor M González; Ignacio Lizasoain
Journal:  Mol Ther       Date:  2018-06-15       Impact factor: 11.454

5.  Development of HBsAg-binding aptamers that bind HepG2.2.15 cells via HBV surface antigen.

Authors:  Jia Liu; Yan Yang; Bin Hu; Zhi-yong Ma; Hong-ping Huang; Yuan Yu; Shen-pei Liu; Meng-ji Lu; Dong-liang Yang
Journal:  Virol Sin       Date:  2010-02-12       Impact factor: 4.327

Review 6.  Bioanalytical chemistry of cytokines--a review.

Authors:  Julie A Stenken; Andreas J Poschenrieder
Journal:  Anal Chim Acta       Date:  2014-10-12       Impact factor: 6.558

7.  Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.

Authors:  Chi-Hong B Chen; George A Chernis; Van Q Hoang; Ralf Landgraf
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-21       Impact factor: 11.205

Review 8.  Aptamer Technology: Adjunct Therapy for Malaria.

Authors:  Nik Abdul Aziz Nik Kamarudin; Nurul Adila Mohammed; Khairul Mohd Fadzli Mustaffa
Journal:  Biomedicines       Date:  2017-01-04

Review 9.  Chondroprotection and Molecular Mechanism of Action of Phytonutraceuticals on Osteoarthritis.

Authors:  Stanislav Sukhikh; Svetlana Noskova; Svetlana Ivanova; Elena Ulrikh; Alexsander Izgaryshev; Olga Babich
Journal:  Molecules       Date:  2021-04-20       Impact factor: 4.411

Review 10.  Molecular targets in arthritis and recent trends in nanotherapy.

Authors:  Kislay Roy; Rupinder Kaur Kanwar; Jagat Rakesh Kanwar
Journal:  Int J Nanomedicine       Date:  2015-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.